← Back to Search

Interbody Device

Tritanium C Cage for Degenerative Disc Disease (STRYKER Trial)

N/A
Recruiting
Led By Jad G Khalil, MD
Research Sponsored by William Beaumont Hospitals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients undergoing a one or two (contiguous) level primary ACDF between C2-T1
≥ 18 years of age and skeletally mature
Must not have
History of vertebral fracture or osteoporotic fracture
Current treatment with chemotherapy, radiation, immunosuppression or chronic steroid therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months postoperative
Awards & highlights
No Placebo-Only Group

Summary

This trial will study the Stryker Tritanium C interbody device for treating degenerative disc disease at one or two levels in the cervical spine.

Who is the study for?
This trial is for adults over 18 with cervical spine issues like herniated discs or degenerative disc disease, who've tried non-surgical treatments without success. It's not for those needing more than two-level fusion, with severe obesity, infections, certain bone diseases, compromised immune systems due to treatments like chemotherapy or conditions that could affect study participation.
What is being tested?
The study tests the Tritanium C Anterior Cervical Cage in patients undergoing a one or two-level ACDF surgery between the neck and upper back (C2-T1). The goal is to assess how well this device helps bones fuse after surgery and improves patient outcomes.
What are the potential side effects?
While specific side effects aren't listed here, typical risks of spinal fusion include pain at the graft site, nerve injury leading to weakness/numbness/pain, infection risk at the surgical site and potential implant-related complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am having a neck surgery involving 1 or 2 levels from C2 to T1.
Select...
I am 18 years or older and my bones have stopped growing.
Select...
I have neck or arm pain with a severity of 4 or more.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had a fracture in my spine or due to weak bones.
Select...
I am currently on chemotherapy, radiation, or taking immunosuppressants or steroids.
Select...
I need surgery to fuse more than two sections of my neck vertebrae.
Select...
I need urgent treatment for a neck injury.
Select...
I have a bone condition that prevents me from having spinal surgery.
Select...
I do not have any ongoing serious infections.
Select...
I have had surgery to fuse bones in my neck.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months postoperative
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months postoperative for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of successful cervical fusion measured radiographically
Secondary study objectives
Count of participants with development of pseudoarthrosis by month 12
Count of participants with revision surgery by month 12
Eating Assessment Tool - 10 for Dysphagia
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Tritanium C Anterior Cervical CageExperimental Treatment1 Intervention
50 subjects undergoing anterior cervical discectomy and fusion surgery using the Tritanium C Cervical Cage at one or two-levels

Find a Location

Who is running the clinical trial?

William Beaumont HospitalsLead Sponsor
151 Previous Clinical Trials
112,560 Total Patients Enrolled
Stryker SpineIndustry Sponsor
6 Previous Clinical Trials
5,315 Total Patients Enrolled
Jad G Khalil, MDPrincipal InvestigatorBeaumont Health
2 Previous Clinical Trials
59 Total Patients Enrolled

Media Library

Tritanium C Anterior Cervical Cage (Interbody Device) Clinical Trial Eligibility Overview. Trial Name: NCT04214535 — N/A
Cervical Disc Degeneration Clinical Trial 2023: Tritanium C Anterior Cervical Cage Highlights & Side Effects. Trial Name: NCT04214535 — N/A
Tritanium C Anterior Cervical Cage (Interbody Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04214535 — N/A
Cervical Disc Degeneration Research Study Groups: Tritanium C Anterior Cervical Cage
~0 spots leftby Dec 2024